SG11201705585QA - Anti-myostatin antibodies and methods of use - Google Patents

US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING. DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody. GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates JP3951062B2 (en) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド Expression of antibody fragments with cysteine present at least as a free thiol in E. coli for the production of bifunctional F (ab ') 2 antibodies US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells ATE295420T1 (en) 1992-02-06 2005-05-15 Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT DE69303494T2 (en) 1992-11-13 1997-01-16 Idec Pharma Corp THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES AGAINST HUMAN B LYMPHOCYTIC LIMITED DIFFERENTIATION ANTIQUES FOR THE TREATMENT OF B CELL LYMPHOMA US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides ES2201076T3 (en) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine GROWTH DIFFERENTIATION FACTOR-8. AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies FR2707189B1 (en) 1993-07-09 1995-10-13 Gradient Ass Method for treating combustion residues and installation for implementing said method. DE4419399C1 (en) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Process for the preparation of heterologous bispecific antibodies US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies JP4213224B2 (en) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド Method for producing multispecific antibody having heteromultimer and common component US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation JP2002506353A (en) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド Methods and compositions for galactosylated glycoproteins US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies ATE531812T1 (en) 1997-12-05 2011-11-15 Scripps Research Inst HUMANIZATION OF RODENT ANTIBODIES US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants PT1068241E (en) 1998-04-02 2007-11-19 Genentech Inc Antibody variants and fragments thereof AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function MX353234B (en) 1999-01-15 2018-01-08 Genentech Inc Polypeptide variants with altered effector function. ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy PROCESS FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes ES2274823T3 (en) 1999-12-29 2007-06-01 Immunogen, Inc. COTOTOXIC AGENTS THAT INCLUDE DOXORRUBICINAS AND DAUNORRUBICINAS AND ITS THERAPEUTIC USE. PT2857516T (en) 2000-04-11 2017-08-28 Genentech Inc Multivalent antibodies and uses therefor WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity PL218428B1 (en) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Cells producing antibody compositions AU2002213251B2 (en) 2000-10-16 2007-06-14 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells ES2295228T3 (en) 2000-11-30 2008-04-16 Medarex, Inc. TRANSGROMIC TRANSCROMOSOMIC ROLLERS FOR THE PREPARATION OF HUMAN ANTIBODIES. DK1355919T3 (en) 2000-12-12 2011-03-14 Medimmune Llc Molecules with longer half-lives, compositions and uses thereof US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof DE60232265D1 (en) 2001-10-25 2009-06-18 Genentech Inc GLYCOPROTEIN COMPOSITIONS US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20 US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation EP1498485A4 (en) 2002-04-09 2006-09-06 Kyowa Hakko Kogyo Kk Cells with modified genome DE60336548D1 (en) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP FUCOSET TRANSPORT CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Drug containing antibody composition US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries DK1553975T3 (en) 2002-09-27 2012-05-07 Xencor Inc Optimized Fc variants and methods for their generation. US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis DK1562972T3 (en) 2002-10-15 2010-12-06 Facet Biotech Corp Modification of FcRn binding affinities or serum half-lives for antibodies by mutagenesis US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis AR047392A1 (en) * 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Fused protein composition AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase JP2007531707A (en) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド Modification of Fc fusion protein serum half-life by mutagenesis of heavy chain constant region positions 250, 314 and / or 428 of IG AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers RS55723B1 (en) 2003-11-05 2017-07-31 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition EA014112B1 (en) 2004-03-23 2010-10-29 Эли Лилли Энд Компани Anti-myostatin monoclonal antibodies and methods of using thereof US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids JP5128935B2 (en) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド Humanized anti-TGF-β antibody WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses EP2067789A1 (en) 2004-04-13 2009-06-10 F. Hoffmann-La Roche Ag Anti-P selectin antibodies AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc. Optimized Fc variants US20060067930A1 (en) 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations. EP1812068A4 (en) 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions KR101019525B1 (en) 2004-11-12 2011-03-07 젠코어 인코포레이티드 Fc VARIANTS WITH ALTERED BINDING TO FcRn US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn DK1772465T3 (en) 2005-01-05 2009-05-25 F Star Biotech Forsch & Entw Synthetic immunoglobulin domains with modified binding properties in regions of the molecule that are not complementarity determining regions JP5620626B2 (en) 2005-03-31 2014-11-05 中外製薬株式会社 Polypeptide production method by association control EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODIES DIRECTED AGAINST MYOSTATIN PT1915397E (en) 2005-08-19 2015-04-30 Univ Pennsylvania Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds ME01786B (en) 2006-08-14 2014-09-20 Xencor Inc Optimized antibodies that target cd19 US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells DK3059246T3 (en) 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR RU2445366C2 (en) 2007-09-28 2012-03-20 Чугаи Сейяку Кабусики Кайся Glypican-3 antibodies with improved kinetic plasma values PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8 EP4269443A3 (en) 2007-12-26 2023-12-27 Xencor, Inc. Fc variants with altered binding to fcrn ES2774337T3 (en) 2008-01-07 2020-07-20 Amgen Inc Method for manufacturing heterodimeric Fc molecules of antibodies using electrostatic conduction effects HRP20240722T1 (en) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly WO2010045193A1 (en) 2008-10-14 2010-04-22 Genentech, Inc. Immunoglobulin variants and uses thereof UY32341A (en) 2008-12-19 2010-07-30 Glaxo Group Ltd NEW ANTIGEN UNION PROTEINS EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens TWI667346B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance RS65965B1 (en) 2010-04-20 2024-10-31 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof JO3340B1 (en) 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8 UY33421A (en) * 2010-06-03 2011-12-30 Glaxo Wellcome House HUMANIZED ANTIGEN UNION PROTEINS CN105585630B (en) 2010-07-29 2020-09-15 Xencor公司 Antibodies with modified isoelectric points KR101973930B1 (en) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain RU2658504C9 (en) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Antigen-binding molecule, that is capable of multiple binding with a lot of antigenic molecules WO2012132067A1 (en) 2011-03-30 2012-10-04 中外製薬株式会社 Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody US20140335089A1 (en) 2011-09-30 2014-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens KR102528622B1 (en) 2011-09-30 2023-05-04 추가이 세이야쿠 가부시키가이샤 Ion concentration-dependent binding molecule library TW201817745A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance CN113416257A (en) 2011-11-30 2021-09-21 中外制药株式会社 Drug comprising transporter (carrier) that enters into cell to form immune complex EP2818183B1 (en) 2012-02-24 2020-04-01 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc RIIB CN104487457B (en) 2012-05-30 2018-01-26 中外制药株式会社 Target tissue specific antigen binding molecule EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens SG11201408042YA (en) 2012-06-15 2015-01-29 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor JP6501521B2 (en) 2012-08-24 2019-04-17 中外製薬株式会社 FcγRIIb-specific Fc region variant JP6096506B2 (en) 2012-12-27 2017-03-15 ゲイツ・ユニッタ・アジア株式会社 Belt mounting jig EP2970508A4 (en) 2013-03-15 2016-12-14 Permeon Biologics Inc Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use CN105246914B (en) 2013-04-02 2021-08-27 中外制药株式会社 Fc region variants JP6153801B2 (en) 2013-07-23 2017-06-28 旭化成ホームズ株式会社 nozzle JP2015185254A (en) 2014-03-20 2015-10-22 日立マクセル株式会社 Nonaqueous electrolyte secondary battery JP5827733B2 (en) 2014-09-10 2015-12-02 日本放送協会 Transmitter CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof PE20171111A1 (en) * 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd ANTIMIOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT HR REGIONS, AND METHODS OF USE WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof PT3368069T (en) * 2016-06-13 2020-11-11 Scholar Rock Inc Use of myostatin inhibitors and combination therapies TWI611811B (en) * 2016-06-17 2018-01-21 中外製藥股份有限公司 Anti-myostatin antibody and method of use